CL
NVAX icon

Croft-Leominster’s Novavax NVAX Stock Holding History

Croft-Leominster’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4,050
Closed -$588K – 152
2016
Q2 		$588K Hold
4,050
– – 0.13% 89
2016
Q1 		$417K Buy
4,050
+1,750
+76% +$188K 0.09% 113
2015
Q4 		$385K Buy
2,300
+300
+15% +$46.2K 0.08% 119
2015
Q3 		$283K Buy
2,000
+850
+74% +$191K 0.07% 134
2015
Q2 		$256K Hold
1,150
– – 0.05% 149
2015
Q1 		$190K Sell
1,150
-500
-30% -$81.2K 0.04% 175
2014
Q4 		$196K Hold
1,650
– – 0.03% 176
2014
Q3 		$137K Hold
1,650
– – 0.02% 186
2014
Q2 		$152K Hold
1,650
– – 0.03% 180
2014
Q1 		$149K Sell
1,650
-350
-18% -$39.1K 0.02% 181
2013
Q4 		$205K Hold
2,000
– – 0.03% 180
2013
Q3 		$126K Buy
+2,000
New +$113K 0.02% 174

Other funds holding NVAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Croft-Leominster's NVAX Position: Q3 2016 in Review

Croft-Leominster sold out of Novavax (NVAX) in Q3 2016, closing a stake of 4,050 shares — an estimated $588K sold.

Croft-Leominster first reported a position in NVAX in Q3 2013 and held it in 12 quarters. The position peaked at $588K in Q2 2016. 165 funds tracked by Wall St. Rank hold NVAX as of Q3 2016.

  • Croft-Leominster reported no remaining Novavax position as of Q3 2016 after selling out during the quarter.
  • Croft-Leominster sold 4,050 Novavax shares in Q3 2016, an estimated $588K.
  • Croft-Leominster first reported a position in Novavax in Q3 2013 and held it in 12 quarters.
  • Croft-Leominster's Novavax position peaked at $588K in Q2 2016.
  • 165 funds tracked by Wall St. Rank held Novavax as of Q3 2016.

Based on Croft-Leominster's 13F filing for Q3 2016, filed 15 Nov 2016.